BACKGROUND: Although sexual dysfunction is common after hematopoietic stem cell transplantation (HCT), interventions to address sexual function are lacking. METHODS: We conducted a pilot study to assess the feasibility and preliminary efficacy of a multimodal intervention to address sexual dysfunction in allogeneic HCT survivors. Transplant clinicians screened HCT survivors 3 months post-HCT for sexual dysfunction causing distress. Those who screened positive attended monthly visits with a trained transplant clinician who: 1) performed an assessment of the causes of sexual dysfunction; 2) educated and empowered the patient to address his or her sexual concerns; and 3) implemented therapeutic interventions targeting the patient's needs. Feasibility was defined as having approximately 75% of patients who screened positive agreeing to participate and 80% attending at least 2 intervention visits. We administered the Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function and satisfaction measure, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and the Hospital Anxiety and Depression Scale (HADS) to evaluate sexual function, quality of life (QOL), and mood, respectively, at baseline and 6 months postintervention. RESULTS: Approximately 33.1% of patients (50 of 151 patients) screened positive for sexual dysfunction causing distress and 94.0% (47 of 50 patients) agreed to participate, with 100% attending 2 intervention visits. Participants reported improvements in satisfaction (P<.0001) and interest in sex (P<.0001), as well as orgasm (P<.0001), erectile function (P<.0001), vaginal lubrication (P 5 .0001), and vaginal discomfort (P 5 .0005). At baseline, approximately 32.6% of participants were not sexually active, compared with 6.5% after the intervention (P 5 .0005). Participants reported improvement in their QOL (P<.0001), depression (P 5 .0002), and anxiety (P 5 .0019). CONCLUSIONS: A multimodal intervention to address sexual dysfunction integrated within the transplant clinic is feasible with encouraging preliminary efficacy for improving sexual function, QOL, and mood in HCT survivors. Cancer 2018;124:2438-46.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for many patients with hematologic conditions. 1, 2 The use of HCT has increased over the last decade, with >20,000 transplantations performed in the United States each year, of which 40% occur in patients aged <45 years. [2] [3] [4] The number of HCT survivors will likely surpass 500,000 by 2030 in the United States alone. 4 HCT survivors experience a drastic deterioration in their sexual function that persists for many years after undergoing HCT. In fact, sexual dysfunction is the most common and persistent complication after HCT, with >40% of male and 60% of female survivors reporting long-term sexual dysfunction posttransplant. [5] [6] [7] [8] Moreover, sexual dysfunction is associated with worse quality of life (QOL), relationship dissatisfaction, and psychological distress. [9] [10] [11] [12] [13] Consequently, the National Institutes of Health Blood and Marrow Transplant Late Effects Initiative identified sexual dysfunction as a major concern facing HCT survivors, thus highlighting the critical need to develop interventions to enhance sexual function in this population.
Despite the prevalence of sexual dysfunction, to our knowledge interventions to improve sexual function in HCT survivors are lacking. 10, 14, 15 Sexual dysfunction often has multiple etiologies, including biologic, interpersonal, psychological, and social factors. 7, 9, [15] [16] [17] [18] [19] [20] [21] [22] Thus, interventions must include a comprehensive assessment and personalized treatment plan to address the diverse sexual health concerns of HCT survivors. 14, 19, 20 However, prior sexual health interventions in other populations typically have addressed either physical or psychological consequences of treatment. 10, [23] [24] [25] In addition, sexual counseling interventions for other cancer survivors generally have been extremely resource-and time-intensive, thereby limiting their potential for dissemination. 25, 26 Therefore, a personalized approach that addresses the biologic, interpersonal, psychological, and social aspects of sexual dysfunction in HCT survivors in a feasible, patient-centered, and scalable manner within the outpatient oncology setting is critically needed. 10, 14, 15 We conducted a single-arm pilot study to assess the feasibility, acceptability, and preliminary efficacy of a multimodal intervention to address sexual dysfunction in HCT survivors. We trained transplant clinicians to deliver the intervention to ensure our care model was sustainable and to promote later dissemination.
MATERIALS AND METHODS

Study Procedures
From September 20, 2015, to January 30, 2017, we screened 151 allogeneic HCT recipients and subsequently enrolled 47 of them at Massachusetts General Hospital (MGH) (ClinicalTrials.gov identifier NCT02492100). We chose to use a single-arm pilot design because prior research has shown that sexual dysfunction does not resolve with the passage of time without intervention. 25, 27 A research assistant screened the weekly transplant clinic schedule to identify potentially eligible patients. The research assistant then informed the transplant clinician that the patient was potentially eligible for this study and inquired about concerns regarding his or her participation. If the clinician had no concerns, the research assistant attached a notification form to the patient's paper chart upon arrival to the transplant clinic. The form instructed the transplant clinician to screen the patient for sexual dysfunction using the 2 items from the National Comprehensive Cancer Network survivorship guideline: 1) do you have problems with sexual function? and 2) are these problems causing you distress? The transplant clinician then offered study participation for those patients who answered both screening questions affirmatively. The research assistant then reviewed the consent form with interested patients, and obtained written informed consent from those who were eligible for the study. Study participants completed baseline self-reported assessments immediately or within 72 hours of providing informed consent. Patients who completed baseline questionnaires then were registered with the Quality Assurance Office for Clinical Trials and scheduled for their first intervention visit. This study was approved by the Dana-Farber/Harvard Cancer Center institutional review board.
Participants
Patients aged 18 years diagnosed with a hematologic malignancy who underwent an allogeneic HCT at least 3 months before study enrollment were eligible to participate. Patients must have screened positive for sexual dysfunction causing distress as noted above and be able to speak English or complete questionnaires with minimal assistance required from an interpreter or family member. We excluded patients with recurrent disease after HCT and those with significant psychiatric or comorbid disease that prohibited adherence to study procedures.
Training of the Study Interventionists
Before initiation of the study, 2 transplant clinicians (1 female physician and 1 women advance practice nurse) were trained to deliver the intervention. The director of the MGH Cancer Center Sexual Health Clinic (D.D.) developed and supervised the training. The interventionists: 1) reviewed the existing literature regarding assessing and treating sexual dysfunction in cancer survivors; 2) participated in a 2-hour training with the director (D.D.) to develop a systematic approach to assess and address the sexual health concerns of patients; and 3) attended 2 days in the sexual health clinic with the director (D.D.) to obtain clinical experience in evaluating and treating patients with sexual dysfunction.
The Multimodal Sexual Dysfunction Intervention
Study participants attended their first intervention visit within 1 month of enrollment. The intervention entailed monthly visits with the study interventionists who: 1) performed an in-depth assessment of the causes of patients' sexual dysfunction; 2) educated, normalized, and empowered patients to address their sexual health concerns; and 3) implemented therapeutic interventions targeting their specific sexual health needs (see Supporting Table 1 ). The interventionists focused on addressing the causes of sexual dysfunction shown to be prevalent in this population, including hormonal deficiencies, erectile dysfunction, vaginal atrophy, dyspareunia, chronic graft-versus-host disease (GVHD) affecting the genitals, and medicationinduced sexual dysfunction. The interventionists performed a gynecological examination for female participants when appropriate to address the causes of their sexual dysfunction. The interventionists also focused on providing psychoeducation to address psychological etiologies for sexual dysfunction, including depression, anxiety, body image concerns, loss of intimacy, and problems with interpersonal relationships and communication. Participants attended at least 2 and a maximum of 6 monthly visits during the study period. Participants who reported complete resolution of their sexual dysfunction after 2 visits were not required to attend additional visits. The first intervention visit was conducted in person in the outpatient transplant clinic. Subsequent visits could be conducted in person or over the telephone. The research team made every effort to schedule the intervention visits on the same day as scheduled appointments in the cancer center. Participants with more complicated sexual health concerns were referred to the sexual health clinic for further evaluation. After each encounter, the interventionist documented the topics covered during the visit, as well as the therapies they recommended to address the participants' sexual health concerns using Research Electronic Data Capture (REDCap).
Study Measures
Participants completed study questionnaires at baseline before the intervention and at 6 months postintervention.
Patient-Reported Measures
We used the Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function and satisfaction measures to assess male and female sexual function. This well-validated measure includes the following domains: global satisfaction with sex life, interest in sexual activity, orgasm, erectile function (for males), vaginal lubrication (for females), and vaginal discomfort (for females). 28 If a participant reports not having sexual activity on a particular domain, their composite score for that domain cannot be calculated and is not evaluable. However, their lack of sexual activity can be reported descriptively. 28 We used the 47-item Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) to assess patients' QOL. 29 The FACT-BMT is comprised of 5 subscales assessing physical, functional, emotional, and social well-being, as well as BMT-specific concerns. A 5-point change in the FACT-BMT is considered clinically significant. 29, 30 We measured patients' anxiety and depression symptoms with the 14-item Hospital Anxiety and Depression Scale (HADS). The HADS consists of 2 subscales assessing anxiety (HADS-A) and depression (HADS-D), with subscale scores ranging from 0 (no distress) to 21 (maximum distress). 31 We also assessed mood using the Patient Health Questionnaire-9 (PHQ-9), a 9-item measure that detects symptoms of major depressive disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). 32 We also conducted exit interviews with 15 participants after they completed their 6-month postintervention questionnaire to assess: 1) their perception of the acceptability and content of the sexual dysfunction intervention; 2) their perception of the intervention efficacy; and 3) the optimal timing for intervention delivery during the survivorship course. We chose participants for the exit interviews randomly while ensuring adequate representation by sex. We reached thematic saturation after conducting 15 exit interviews.
Demographic and Clinical Factors
Participants also completed a baseline demographic questionnaire to indicate their race, sex, relationship status, education, and income. We reviewed patients' electronic health records to obtain their cancer diagnosis, date of transplantation, conditioning regimen intensity, and whether they had chronic GVHD.
Statistical Analysis
We performed statistical analyses using STATA statistical software (version 9.3; StataCorp LLC, College Station, Texas). The primary endpoint of the study was feasibility. We chose the sample size for the study based on the feasibility of completing the project during the proposed timeframe and achieving the feasibility endpoint. The proposed intervention was deemed feasible if: 1) at least 75% of the patients who screened positive for sexual dysfunction causing distress agreed to participate in the study and attended the first scheduled intervention visit; and 2) at least 80% of enrolled participants attended at least 2 intervention visits. For all analyses, we considered 2-sided P values <.05 to be statistically significant.
The secondary endpoints were to evaluate the preliminary efficacy of the intervention by examining changes in patient-reported outcomes from baseline to 6
Original Article months. We used the Student t test for paired data to examine the change in sexual function (PROMIS measure domains), QOL (FACT-BMT), and psychological distress (HADS and PHQ-9) from baseline to 6 months after the intervention. We used the McNemar test to examine the difference in the percentage of participants who were not sexually active before the intervention compared with after the intervention. Only 1 participant had missing data at 6 months (due to death from disease recurrence), and therefore we did not need to conduct imputations for missing data.
RESULTS
Participant Characteristics
Transplant clinicians systematically screened 151 allogeneic HCT recipients for sexual dysfunction causing distress and identified 50 patients (33.1%) who screened positive. The majority of patients (47 of 50; 94.0%) who screened positive agreed to participate and enrolled in the study (Fig. 1) . The reasons for nonenrollment were disease recurrence (1 patient), not interested (1 patient), and lack of time (1 patient). Enrolled participants were mostly white (93.6%), with a median age of 52.5 years (range, 24-75 years) and 51.1% were female ( Table 1) . The median time from transplant to enrollment was 29 months (range, 3-173 months). The majority of participants (30 of 47 participants; 63.8%) had chronic GVHD. All participants completed baseline study assessments. At 6 months after the intervention, only 1 patient had missing data due to disease recurrence and death.
Feasibility of the Intervention
Overall, 94.0% of patients (47 of 50 patients) who screened positive for sexual dysfunction causing distress agreed to participate in the study, and all participants attended at least 2 intervention visits. The median number of visits was 2 (range, 2-5 visits). The median duration of the first and second visits were 50 minutes (range, 20-120 minutes) and 30 minutes (range, 15-90 minutes), respectively. The trained transplant nurse practitioner conducted approximately 41.7% of the intervention visits. Approximately one-half of the follow-up intervention visits occurred over the telephone (47.9%; 35 of 73 visits). Only 3 participants (6.4%) required referral to the sexual health clinic. A minority of participants (28%; 13 of 47 participants) had a partner attend an intervention visit. Figure 2 depicts the topics covered during the first intervention visit with male participants (23 participants) and the therapies recommended to address these issues. The most common topics addressed with males were erectile dysfunction (87%), loss of libido (48%), difficulty with arousal (39%), intimacy concerns (30%), ejaculatory disorders (13%), and psychological concerns (13%). The most common therapies recommended for males included phosphodiesterase inhibitors on demand (57%), psychoeducation and counseling (52%), and penile constriction rings (48%). Figure 3 depicts the topics covered during the first intervention visit with female participants (24 participants) and the therapies recommended to address these issues. The most common topics addressed with females were pain with intercourse (75%), loss of libido (38%), GVHD (33%), psychological concerns (25%), intimacy concerns (25%), difficulty with arousal (21%), and body image concerns (17%). The most common therapies recommended for females included vaginal estrogen (67%), dilators (63%), lubricants (58%), psychoeducation and counseling (42%), and topical treatment for GVHD (42%).
Patient-Reported Sexual Function
At baseline, 32.6% participants (15 of 46 participants) were not having sexual activity. After the intervention, only 6.5% of participants (3 of 46 participants) reported not being sexually active (P 5.0005) (Fig. 4) . Participants who were sexually active reported significant improvements in their global satisfaction with sex (P<.0001), interest in sex (P<.0001), and orgasm (P<.0001) ( Table  2 ). Both male and female participants reported improvements in these outcomes without significant differential effects of the intervention by sex. In addition, male participants also reported a significant improvement in their erectile function postintervention (P<.0001), whereas Table 2 ). There were no differences noted in the improvements in patient-reported QOL and mood by sex.
Acceptability of the Intervention
In exit interviews, all participants (15 of 15) reported that the intervention visits were very convenient because they occurred during their scheduled appointments or via telephone. Participants appreciated the flexibility of having the option of conducting subsequent intervention visits over the telephone. The majority of participants (14 of 15) were satisfied with the frequency, timing, and duration of the intervention visits. Some participants commented that the intervention should be implemented as early as possible after transplant. All participants reported that the intervention was extremely helpful in addressing their sexual health concerns. 
DISCUSSION
In the current study, we observed that sexual dysfunction was quite common, affecting approximately one-third of allogeneic HCT survivors. We also demonstrated that a multimodal intervention delivered by trained transplant clinicians to address and treat sexual dysfunction in HCT survivors is feasible and acceptable, with promising efficacy. Greater than 94% of patients who screened positive for sexual dysfunction causing distress agreed to participate in the study, and 100% participated in at least 2 intervention visits. The intervention led to substantial and clinically significant improvements in patient-reported global satisfaction with sex, interest in sex, orgasm, erectile function, vaginal lubrication, and vaginal discomfort, as well as QOL and symptoms of depression and anxiety. Participants found the intervention to be highly acceptable, convenient, and helpful in addressing their sexual health concerns. These encouraging findings warrant further testing in a randomized clinical trial.
To our knowledge, the current study is the first in which transplant clinicians systematically screened HCT survivors for sexual dysfunction causing distress. Survivors often report that they have no communication with their clinicians regarding their sexual health concerns. 5, 18, [33] [34] [35] [36] The results herein demonstrated that transplant clinicians can effectively screen for and talk about sexual dysfunction with their patients during routine clinic visits. It is interesting to note that approximately one-third of HCT survivors screened positive for sexual dysfunction causing distress, thereby underscoring the frequency of sexual health concerns among these individuals. These findings highlight both the importance and feasibility of integrating screening for sexual dysfunction within the routine practice of the transplant clinic.
Importantly, this intervention was delivered by transplant clinicians with no expertise in sexual health who invested a relatively short amount of time in training to address sexual health concerns for HCT survivors. Only 3 participants required referral for more specialized care, further demonstrating the feasibility of this approach in addressing the majority of sexual health concerns in HCT survivors. This model of care has the potential to be highly sustainable and easily disseminated because oncology clinicians in various practices can be trained to address the sexual health concerns of their patients without the need for more specialized care. These findings are particularly relevant given the lack of specialized clinics to address the sexual health concerns of cancer survivors. 6, 19 The multimodal intervention used herein was shown to be feasible and highly acceptable to HCT survivors. The intervention was delivered and integrated within the outpatient clinic for HCT survivors as they received their routine care. Considering that these patients experience a significant burden coordinating their care and attending multiple outpatient appointments, 14 integrating the intervention during routine outpatient transplant care ensures that it is convenient and accessible for this population. We also observed promising preliminary efficacy data of the intervention, with significant improvements noted in all patient-reported outcomes with large effect sizes. To our knowledge, this is the first intervention to demonstrate improvements in all sexual health domains. These results likely are due in part to the personalized and multimodal approach the interventionists used to address patients' sexual health concerns. Experts have strongly recommended using a multimodal approach to address the many etiologies of sexual dysfunction in cancer survivors. 10, 14, 15 The intervention also led to remarkable improvements in patientreported QOL and symptoms of depression and anxiety. These findings highlight the central role sexuality plays in affecting patient QOL and mood. [10] [11] [12] [13] Studies have shown that sexual dysfunction is associated with relationship discord, intimacy problems, and worse QOL and mood. [9] [10] [11] [12] [13] 37, 38 Therefore, improving patients' sexual function after transplant may have a positive effect on their intimate relationships, thereby enhancing their QOL and physical and psychological health. Because many HCT survivors struggle with long-term QOL impairments and psychological distress, [39] [40] [41] [42] the results are especially noteworthy and warrant further investigation. In future studies, investigators also should explore whether improvement in sexual function mediates the effect of the intervention on QOL and mood in this population.
The current study has several important limitations. First, there was a relatively small sample of mainly white and educated patients who were receiving their care at a single transplant center, thereby potentially limiting the generalizability of the results to other care settings and populations. Second, although the findings of the current study are promising, the lack of a control group limited our ability to conclude definitively that improvements in sexual function were not due merely to the passage of time. However, prior research has shown that time alone does not ameliorate sexual dysfunction. 25, 27 Nonetheless, randomized controlled trials are needed to demonstrate the efficacy of the multimodal intervention in enhancing sexual function, QOL, and mood in HCT survivors. Third, there currently are no long-term follow-up data with which to assess whether the effects of the intervention on patient-reported outcomes are sustainable. Future studies should include longer-term follow-up assessments of these outcomes.
The results of the current study demonstrate that a multimodal intervention delivered by trained transplant clinicians is feasible and acceptable, with promising preliminary efficacy in improving sexual function, QOL, and mood in HCT survivors. Importantly, we demonstrated that screening for sexual dysfunction can be easily integrated into routine transplantation care. Moreover, we successfully trained transplant clinicians to address the majority of sexual health concerns in HCT survivors, thereby testing a highly feasible, accessible, and potentially disseminable model for addressing sexual dysfunction in these individuals. A future randomized clinical trial to demonstrate the efficacy of this care model in enhancing sexual function and improving the QOL and care for HCT survivors clearly is warranted.
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